This anti-proliferative activity is surprising given the well-established oncogenic role of Ruvbl2 in a variety of cancers including renal, liver, lung, stomach, pancreas, and blood (Mao and Houry, 2017). This evidence concerns the gene RUVBL2 and cancer.